Skip to main content

Alert COVID-19

Please find service updates and current visiting rules in our COVID-19 section.

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

Drug monitoring guidelines

Variations in monitoring requirements may occur and this should be read in conjunction with:

  • medication specific information provided by the rheumatology unit
  • manufacturer's data sheet.

If you have any concerns or queries regarding your patient's blood monitoring please contact us.

If you advise a patient to withhold medication please let us know for our records:

Contact us

For details of standard drug monitoring for patients on long-term treatment please refer to:

Oxfordshire CCG Shared Care Guidance 'Rheumatology Monitoring General Guidance'.

For specific advice on methotrexate use please see:

British Society for Rheumatology guidelines.

For information on monitoring of biologics in children and adolescents please see:

British Society for Rheumatology guidelines.

Last reviewed:04 February 2022